Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein

[1]  P. Fraser,et al.  α‐Synuclein–synaptosomal membrane interactions , 2004 .

[2]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[3]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .

[4]  C. Haass,et al.  α-Synuclein Has a High Affinity for Packing Defects in a Bilayer Membrane , 2004, Journal of Biological Chemistry.

[5]  B. A. Hamilton.  alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. , 2004, Genomics.

[6]  D. Eliezer,et al.  Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-Synuclein , 2004 .

[7]  B. Davletov,et al.  Synaptotagmin Interaction with the Syntaxin/SNAP-25 Dimer Is Mediated by an Evolutionarily Conserved Motif and Is Sensitive to Inositol Hexakisphosphate* , 2004, Journal of Biological Chemistry.

[8]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[9]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[10]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[11]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[12]  Jie Li,et al.  The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.

[13]  Ralf Langen,et al.  Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.

[14]  D. Eliezer,et al.  A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. , 2003, Journal of molecular biology.

[15]  Min Zhu,et al.  Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.

[16]  Reinhard Jahn,et al.  A Broken α-Helix in Folded α-Synuclein* , 2003, The Journal of Biological Chemistry.

[17]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[18]  R. Nussbaum,et al.  Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.

[19]  P. S. St George-Hyslop,et al.  Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein , 2002 .

[20]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[21]  R. Perrin,et al.  Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.

[22]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[23]  Rebecca A. Betensky,et al.  α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Scarlata,et al.  Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.

[25]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[26]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[27]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[28]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[29]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[30]  Susan E Daniel,et al.  Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.

[31]  R. Crowther,et al.  Abnormal tau-containing filaments in neurodegenerative diseases. , 2000, Journal of structural biology.

[32]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[35]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[36]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[37]  R. Jakes,et al.  Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.

[38]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[39]  R. Anthony Crowther,et al.  Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .

[40]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[41]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[42]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[43]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[44]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[45]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[46]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[47]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[48]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[49]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[50]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[51]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[52]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[53]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Crowther.  Straight and paired helical filaments in Alzheimer disease have a common structural unit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Macdonald,et al.  Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. , 1991, Biochimica et biophysica acta.

[56]  M. Hosokawa,et al.  Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. , 1989, Analytical biochemistry.

[57]  M. Bally,et al.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. , 1985, Biochimica et biophysica acta.

[58]  D. Michaelson,et al.  Asymmetry of lipid organization in cholinergic synaptic vesicle membranes. , 1983, The Biochemical journal.

[59]  C. E. Dalgliesh,et al.  Gas-liquid chromatographic study and estimation of several urinary aromatic acids. , 1966, Analytical biochemistry.